Big news if you are someone who uses a Continuous Glucose Monitor (CGM). On October 4th the highly anticipated Dexcom G7 was launched in several countries with more to come in the coming weeks. Check out their launch video here.
Dexcom G7 is now available for people ages 2 and up, in five additional countries – the United Kingdom, Ireland, Germany Austria and Hong Kong. The G7 has been submitted for FDA review in the US, with the company hoping for a US launch before the end of 2022. Stay tuned for updates on the timeline for Health Canada approval for Canadian CIM community members.
“Since Dexcom G6 came to market, we’ve eliminated over 15 billion fingerpricks and helped improve the lives of more than 1.25 million people with diabetes around the world. We’re thrilled to begin the global rollout of Dexcom G7, our next-generation CGM technology, that vastly improves upon what everyone loves about G6,” said Kevin Sayer, chairman, president and CEO of Dexcom. “Dexcom CGM has become the gold standard of care for diabetes, and bringing our technology to more and more people around the world continues to be a top priority. With this initial launch behind us, we look forward to introducing G7 in additional markets and bringing this life-changing technology to as many people as we can.”
We gave a detailed runthrough of the new elements of the G7 in a previous blog post, available here, but here is a reminder of the new features and benefits of the G7.
- It’s the size of a nickel, and thinner than before.
- It warms up 4 times quicker than the Dexcom G6 (from 2 hours down to 30 mins)
- It has a 12-hour grace period to replace finished sensors for a more seamless transition between sessions.
- A redesigned and simplied mobile app with Dexcom Clarity integration to help you and your healthcare team more easily monitor clinically important information
- Easier sensor application.
- It has less packaging.
- Future software updates are expected to allow direct to Apple Watch interface
